{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:56:11Z","timestamp":1777564571754,"version":"3.51.4"},"reference-count":94,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T00:00:00Z","timestamp":1677024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III (ISCIII), the Spanish Ministry of Science and Innovation","doi-asserted-by":"publisher","award":["CD21\/00022"],"award-info":[{"award-number":["CD21\/00022"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fundaci\u00f3n HNA, 2nd edition of the Scientific Health Research Award","award":["CD21\/00022"],"award-info":[{"award-number":["CD21\/00022"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Huntington\u2019s disease (HD) is an autosomal dominant progressive brain disorder, caused by a pathological expansion of a CAG repeat that encodes the huntingtin gene. This genetic neurodegenerative rare disease is characterized by cognitive, motor, and neuropsychiatric manifestations. The aim of the treatment is symptomatic and addresses the hyperkinetic disorders (chorea, dystonia, myoclonus, tics, etc.) and the behavioural and cognitive disturbances (depression, anxiety, psychosis, etc.) associated with the disease. HD is still a complex condition in need of innovative and efficient treatment. The long-term goal of pharmacogenetic studies is to use genotype data to predict the effective treatment response to a specific drug and, in turn, prevent potential undesirable effects of its administration. Chorea, depression, and psychotic symptoms have a substantial impact on HD patients\u2019 quality of life and could be better controlled with the help of pharmacogenetic knowledge. We aimed to carry out a review of the available publications and evidence related to the pharmacogenetics of HD, with the objective of compiling all information that may be useful in optimizing drug administration. The impact of pharmacogenetic information on the response to antidepressants and antipsychotics is well documented in psychiatric patients, but this approach has not been investigated in HD patients. Future research should address several issues to ensure that pharmacogenetic clinical use is appropriately supported, feasible, and applicable.<\/jats:p>","DOI":"10.3390\/jpm13030385","type":"journal-article","created":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T04:33:56Z","timestamp":1677040436000},"page":"385","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Pharmacogenetics in the Treatment of Huntington\u2019s Disease: Review and Future Perspectives"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6269-7953","authenticated-orcid":false,"given":"Xandra","family":"Garc\u00eda-Gonz\u00e1lez","sequence":"first","affiliation":[{"name":"Pharmacy Department, Instituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n (IiSGM), Hospital General Universitario Gregorio Mara\u00f1\u00f3n, 28007 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Cubo","sequence":"additional","affiliation":[{"name":"Neurology Department, Hospital Universitario de Burgos, 09006 Burgos, Spain"},{"name":"Department of Health Sciences, University of Burgos, 09001 Burgos, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc\u00eda","family":"Sim\u00f3n-Vicente","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, University of Burgos, 09001 Burgos, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natividad","family":"Mariscal","sequence":"additional","affiliation":[{"name":"Neurology Department, Hospital Universitario de Burgos, 09006 Burgos, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel","family":"Alcaraz","sequence":"additional","affiliation":[{"name":"Research Unit, Fundaci\u00f3n Burgos por la Investigaci\u00f3n de la Salud (FBIS), Hospital Universitario de Burgos, 09006 Burgos, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Aguado","sequence":"additional","affiliation":[{"name":"Neurology Department, Hospital Universitario de Burgos, 09006 Burgos, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1725-5304","authenticated-orcid":false,"given":"J\u00e9ssica","family":"Rivadeneyra-Posadas","sequence":"additional","affiliation":[{"name":"Research Unit, Fundaci\u00f3n Burgos por la Investigaci\u00f3n de la Salud (FBIS), Hospital Universitario de Burgos, 09006 Burgos, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Sanz-Solas","sequence":"additional","affiliation":[{"name":"Research Unit, Fundaci\u00f3n Burgos por la Investigaci\u00f3n de la Salud (FBIS), Hospital Universitario de Burgos, 09006 Burgos, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1660-3135","authenticated-orcid":false,"given":"Miriam","family":"Saiz-Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, University of Burgos, 09001 Burgos, Spain"},{"name":"Research Unit, Fundaci\u00f3n Burgos por la Investigaci\u00f3n de la Salud (FBIS), Hospital Universitario de Burgos, 09006 Burgos, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s13023-020-01641-z","article-title":"Research Priorities for Rare Neurological Diseases: A Representative View of Patient Representatives and Healthcare Professionals from the European Reference Network for Rare Neurological Diseases","volume":"16","author":"Post","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1002\/mds.25075","article-title":"The Incidence and Prevalence of Huntington\u2019s Disease: A Systematic Review and Meta-Analysis","volume":"27","author":"Pringsheim","year":"2012","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000445453","article-title":"Pharmacogenetics in Neurodegenerative Diseases: Implications for Clinical Trials","volume":"Volume 39","author":"Beghi","year":"2016","journal-title":"Frontiers of Neurology and Neuroscience"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1212\/WNL.0b013e318263c443","article-title":"American Academy of Neurology Evidence-Based Guideline: Pharmacologic Treatment of Chorea in Huntington Disease: Report of the Guideline Development Subcommittee of the American Academy of Neurology","volume":"79","author":"Armstrong","year":"2012","journal-title":"Neurology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S1471-4914(01)01986-4","article-title":"Clinical Application of Pharmacogenetics","volume":"7","author":"Spear","year":"2001","journal-title":"Trends Mol. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s40264-015-0281-0","article-title":"Epidemiology of Adverse Drug Reactions in Europe: A Review of Recent Observational Studies","volume":"38","author":"Bouvy","year":"2015","journal-title":"Drug Saf."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"734","DOI":"10.3389\/fphar.2020.00734","article-title":"Urgent Hospital Admissions Caused by Adverse Drug Reactions and Medication Errors\u2014A Population-Based Study in Spain","volume":"11","author":"Ochoa","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"73","DOI":"10.4103\/0976-500X.120957","article-title":"Clinical and Economic Burden of Adverse Drug Reactions","volume":"4","author":"Sultana","year":"2013","journal-title":"J. Pharmacol. Pharmacother."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.2174\/1570159X15666170630163616","article-title":"Antipsychotic Drugs: From Receptor-Binding Profiles to Metabolic Side Effects","volume":"16","author":"Siafis","year":"2018","journal-title":"Curr. Neuropharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"PRISMA Group Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement","volume":"62","author":"Moher","year":"2009","journal-title":"J. Clin. Epidemiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/clpt.2012.96","article-title":"Pharmacogenomics Knowledge for Personalized Medicine","volume":"92","author":"McDonagh","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"710","DOI":"10.3389\/fneur.2019.00710","article-title":"International Guidelines for the Treatment of Huntington\u2019s Disease","volume":"10","author":"Ferreira","year":"2019","journal-title":"Front. Neurol."},{"key":"ref_13","unstructured":"Suchowersky, O. (2023, January 11). Huntington Disease: Management. Available online: https:\/\/www.uptodate.com\/contents\/huntington-disease-management."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/cpdd.882","article-title":"Pharmacokinetics of Deutetrabenazine and Tetrabenazine: Dose Proportionality and Food Effect","volume":"10","author":"Schneider","year":"2021","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Huntington Study Group (2006). Tetrabenazine as Antichorea Therapy in Huntington Disease: A Randomized Controlled Trial. Neurology, 66, 366\u2013372.","DOI":"10.1212\/01.wnl.0000198586.85250.13"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1007\/s40263-022-00956-8","article-title":"The Safety of Deutetrabenazine for Chorea in Huntington Disease: An Open-Label Extension Study","volume":"36","author":"Frank","year":"2022","journal-title":"CNS Drugs"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1586\/ern.11.149","article-title":"Tetrabenazine for the Treatment of Chorea and Other Hyperkinetic Movement Disorders","volume":"11","author":"Jankovic","year":"2011","journal-title":"Expert Rev. Neurother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.pharmthera.2007.09.004","article-title":"Influence of Cytochrome P450 Polymorphisms on Drug Therapies: Pharmacogenetic, Pharmacoepigenetic and Clinical Aspects","volume":"116","author":"Sim","year":"2007","journal-title":"Pharmacol. Ther."},{"key":"ref_19","unstructured":"The Pharmacogene Variation (PharmVar) Consortium (2023, February 20). CYP2D6 Allele Nomenclature. Available online: https:\/\/www.pharmvar.org\/gene\/CYP2D6."},{"key":"ref_20","first-page":"215","article-title":"Standardizing Terms for Clinical Pharmacogenetic Test Results: Consensus Terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC)","volume":"19","author":"Caudle","year":"2017","journal-title":"Genet. Med. Off. J. Am. Coll. Med. Genet."},{"key":"ref_21","unstructured":"Clinical Pharmacology. Department of Medicine. Indiana University (2023, January 10). Available online: https:\/\/drug-interactions.medicine.iu.edu\/maintable.aspx."},{"key":"ref_22","unstructured":"(2023, January 24). EMA Scientific Conclusions and Grounds for Variation, Amendments to the Product Information of Tetrabenazine. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/psusa\/tetrabenazinecmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable\/00002911\/201410_en.pdf."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/mds.25278","article-title":"Analysis of CYP2D6 Genotype and Response to Tetrabenazine","volume":"28","author":"Mehanna","year":"2013","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"ref_24","first-page":"1","article-title":"Aripiprazole in the Treatment of Huntington\u2019s Disease: A Case Series","volume":"5","author":"Ciammola","year":"2009","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/mds.22376","article-title":"Treatment of the Symptoms of Huntington\u2019s Disease: Preliminary Results Comparing Aripiprazole and Tetrabenazine","volume":"24","author":"Brusa","year":"2009","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/00002826-200209000-00007","article-title":"Olanzapine for Huntington\u2019s Disease: An Open Label Study","volume":"25","author":"Bonelli","year":"2002","journal-title":"Clin. Neuropharmacol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1046\/j.1468-1331.2002.0354e.x","article-title":"Risperidone in Chorea and Psychosis of Huntington\u2019s Disease","volume":"9","author":"Erdemoglu","year":"2002","journal-title":"Eur. J. Neurol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/10401230490487007","article-title":"Aripiprazole: Review of Its Pharmacology and Therapeutic Use in Psychiatric Disorders","volume":"16","author":"Gupta","year":"2004","journal-title":"Ann. Clin. Psychiatry Off. J. Am. Acad. Clin. Psychiatr."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/PL00005334","article-title":"Metabolism of Risperidone to 9-Hydroxyrisperidone by Human Cytochromes P450 2D6 and 3A4","volume":"359","author":"Fang","year":"1999","journal-title":"Naunyn. Schmiedebergs Arch. Pharmacol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00406-018-0975-2","article-title":"Phenoconversion of CYP2D6 by Inhibitors Modifies Aripiprazole Exposure","volume":"270","author":"Kiss","year":"2020","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s00228-007-0373-6","article-title":"Impact of the CYP2D6 Genotype on Steady-State Serum Concentrations of Aripiprazole and Dehydroaripiprazole","volume":"63","author":"Hendset","year":"2007","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/JCP.0000000000000319","article-title":"The Influence of the CYP3A4*22 Polymorphism and CYP2D6 Polymorphisms on Serum Concentrations of Aripiprazole, Haloperidol, Pimozide, and Risperidone in Psychiatric Patients","volume":"35","year":"2015","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s00228-015-1965-1","article-title":"Genotype and Co-Medication Dependent CYP2D6 Metabolic Activity: Effects on Serum Concentrations of Aripiprazole, Haloperidol, Risperidone, Paliperidone and Zuclopenthixol","volume":"72","author":"Lisbeth","year":"2016","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_34","unstructured":"U.S. Food & Drug Administration (FDA) (2023, January 11). Drugs FDA: FDA-Approved Drugs, Available online: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&varapplno=021436."},{"key":"ref_35","unstructured":"European Medicines Agency (EMA) (2023, January 11). Abilify Maintena. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/epar\/abilify-maintena."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/clpt.2011.34","article-title":"Pharmacogenetics: From Bench to Byte\u2014An Update of Guidelines","volume":"89","author":"Swen","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jpsychires.2008.09.005","article-title":"Effects of DRD2\/ANKK1 Gene Variations and Clinical Factors on Aripiprazole Efficacy in Schizophrenic Patients","volume":"43","author":"Shen","year":"2009","journal-title":"J. Psychiatr. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.euroneuro.2008.07.010","article-title":"APLUS study group Taq1A Polymorphism in the Dopamine D2 Receptor Gene as a Predictor of Clinical Response to Aripiprazole","volume":"18","author":"Kwon","year":"2008","journal-title":"Eur. Neuropsychopharmacol. J. Eur. Coll. Neuropsychopharmacol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/FPC.0b013e3282f3ef8c","article-title":"Taq1A Polymorphism in the Dopamine D2 Receptor Gene Predicts Brain Metabolic Response to Aripiprazole in Healthy Male Volunteers","volume":"18","author":"Kim","year":"2008","journal-title":"Pharmacogenet. Genom."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.psychres.2010.04.017","article-title":"Influence of DAOA Gene Variants on Antipsychotic Response after Switch to Aripiprazole","volume":"178","author":"Pae","year":"2010","journal-title":"Psychiatry Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/JCP.0b013e31828f62cd","article-title":"Pharmacogenetic Study on Risperidone Long-Acting Injection: Influence of Cytochrome P450 2D6 and Pregnane X Receptor on Risperidone Exposure and Drug-Induced Side-Effects","volume":"33","author":"Choong","year":"2013","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1177\/0269881107077357","article-title":"Serum Prolactin Levels, Plasma Risperidone Levels, Polymorphism of Cytochrome P450 2D6 and Clinical Response in Patients with Schizophrenia","volume":"21","author":"Wang","year":"2007","journal-title":"J. Psychopharmacol. Oxf. Engl."},{"key":"ref_43","unstructured":"(2023, January 11). Dutch Pharmacogenetics Working Group (DPWG) Risk Analysis Document for Risperidone and CYP2D6. Available online: https:\/\/www.g-standaard.nl\/risicoanalyse\/b0001536.pdf."},{"key":"ref_44","first-page":"418","article-title":"Pharmacogenetics of Risperidone Therapy in Autism: Association Analysis of Eight Candidate Genes with Drug Efficacy and Adverse Drug Reactions","volume":"10","author":"Correia","year":"2010","journal-title":"Pharm. J."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.2217\/14622416.9.10.1437","article-title":"Variants of Dopamine and Serotonin Candidate Genes as Predictors of Response to Risperidone Treatment in First-Episode Schizophrenia","volume":"9","author":"Ikeda","year":"2008","journal-title":"Pharmacogenomics"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.pnpbp.2014.01.017","article-title":"A Pharmacogenetic Study of Risperidone on Chemokine (C-C Motif) Ligand 2 (CCL2) in Chinese Han Schizophrenia Patients","volume":"51","author":"Xiong","year":"2014","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/YPG.0b013e328358629a","article-title":"Association between a COMT Polymorphism and Clinical Response to Risperidone Treatment: A Pharmacogenetic Study","volume":"22","author":"Zhao","year":"2012","journal-title":"Psychiatr. Genet."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"410","DOI":"10.2174\/138920008784746373","article-title":"Metabolism of Atypical Antipsychotics: Involvement of Cytochrome P450 Enzymes and Relevance for Drug-Drug Interactions","volume":"9","author":"Urichuk","year":"2008","journal-title":"Curr. Drug Metab."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"939","DOI":"10.2217\/pgs-2021-0051","article-title":"The Pharmacogenetics of Treatment with Olanzapine","volume":"22","author":"Zubiaur","year":"2021","journal-title":"Pharmacogenomics"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00228-009-0783-8","article-title":"Carriers of the UGT1A4 142T>G Gene Variant Are Predisposed to Reduced Olanzapine Exposure\u2013an Impact Similar to Male Gender or Smoking in Schizophrenic Patients","volume":"66","author":"Ghotbi","year":"2010","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1192\/bjp.185.2.147","article-title":"Prolactin Levels in Antipsychotic Treatment of Patients with Schizophrenia Carrying the DRD2*A1 Allele","volume":"185","author":"Young","year":"2004","journal-title":"Br. J. Psychiatry J. Ment. Sci."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/FPC.0b013e3283397d06","article-title":"Dopamine Receptor D2 Gene Is Associated with Weight Gain in Schizophrenic Patients under Long-Term Atypical Antipsychotic Treatment","volume":"20","author":"Hong","year":"2010","journal-title":"Pharmacogenet. Genom."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/npp.2009.235","article-title":"A Common Polymorphism in the Cannabinoid Receptor 1 (CNR1) Gene Is Associated with Antipsychotic-Induced Weight Gain in Schizophrenia","volume":"35","author":"Tiwari","year":"2010","journal-title":"Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/YPG.0b013e3283328e06","article-title":"Leptin Gene -2548G\/A Variants Predict Risperidone-Associated Weight Gain in Children and Adolescents","volume":"19","author":"Calarge","year":"2009","journal-title":"Psychiatr. Genet."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1007\/s12325-020-01566-w","article-title":"Metabolic Effects of Aripiprazole and Olanzapine Multiple-Dose Treatment in a Randomised Crossover Clinical Trial in Healthy Volunteers: Association with Pharmacogenetics","volume":"38","author":"Koller","year":"2021","journal-title":"Adv. Ther."},{"key":"ref_56","unstructured":"Nance, M., Paulsen, J.S., Rosenblatt, A., and Wheelock, V. (2011). A Physician\u2019s Guide to the Management of Huntington\u2019s Disease, Huntington\u2019s Disease Society of America. [3rd ed.]."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1124\/dmd.111.042150","article-title":"Human UDP-Glucuronosyltransferase Isoforms Involved in Haloperidol Glucuronidation and Quantitative Estimation of Their Contribution","volume":"40","author":"Kato","year":"2012","journal-title":"Drug Metab. Dispos. Biol. Fate Chem."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2165\/00003088-199937060-00001","article-title":"Pharmacokinetics of Haloperidol: An Update","volume":"37","author":"Kudo","year":"1999","journal-title":"Clin. Pharmacokinet."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1211\/jpp.58.7.0001","article-title":"Role of CYP Pharmacogenetics and Drug-Drug Interactions in the Efficacy and Safety of Atypical and Other Antipsychotic Agents","volume":"58","author":"Murray","year":"2006","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0278-5846(03)00154-4","article-title":"Effects of Smoking and Cytochrome P450 2D6*10 Allele on the Plasma Haloperidol Concentration\/Dose Ratio","volume":"27","author":"Ohara","year":"2003","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1038\/sj.npp.1300213","article-title":"Effect of CYP2D6 Genotypes on the Metabolism of Haloperidol in a Japanese Psychiatric Population","volume":"28","author":"Someya","year":"2003","journal-title":"Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol."},{"key":"ref_62","unstructured":"(2023, January 11). Dutch Pharmacogenetics Working Group (DPWG) Risk Assessment. Available online: https:\/\/api.pharmgkb.org\/v1\/download\/file\/attachment\/dpwg_may_2021.pdf."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1365-2710.2007.00829.x","article-title":"Effects of Genetic Polymorphism of Cytochrome P450 Enzymes on the Pharmacokinetics of Benzodiazepines","volume":"32","author":"Fukasawa","year":"2007","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"949","DOI":"10.2217\/pgs-2022-0161","article-title":"Use of Pharmacogenetics for Benzodiazepine Prescription: State of the Art and Expectations","volume":"23","author":"Zubiaur","year":"2022","journal-title":"Pharmacogenomics"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1176\/appi.ajp.2015.14121551","article-title":"PREDICT-HD Investigators and Coordinators of the Huntington Study Group Longitudinal Psychiatric Symptoms in Prodromal Huntington\u2019s Disease: A Decade of Data","volume":"173","author":"Epping","year":"2016","journal-title":"Am. J. Psychiatry"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Paoli, R., Botturi, A., Ciammola, A., Silani, V., Prunas, C., Lucchiari, C., Zugno, E., and Caletti, E. (2017). Neuropsychiatric Burden in Huntington\u2019s Disease. Brain Sci., 7.","DOI":"10.3390\/brainsci7060067"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1136\/jnnp.71.3.310","article-title":"Neuropsychiatric Aspects of Huntington\u2019s Disease","volume":"71","author":"Paulsen","year":"2001","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.biopsych.2006.11.034","article-title":"Psychiatric Symptoms in Huntington\u2019s Disease before Diagnosis: The Predict-HD Study","volume":"62","author":"Duff","year":"2007","journal-title":"Biol. Psychiatry"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1177\/1039856218791036","article-title":"Huntington\u2019s Disease: Neuropsychiatric Manifestations of Huntington\u2019s Disease","volume":"26","author":"Goh","year":"2018","journal-title":"Australas. Psychiatry"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1177\/1039856218766120","article-title":"Huntington\u2019s Disease: Managing Neuropsychiatric Symptoms in Huntington\u2019s Disease","volume":"26","author":"Loi","year":"2018","journal-title":"Australas. Psychiatry"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/mds.25750","article-title":"Results of the Citalopram to Enhance Cognition in Huntington Disease Trial: Citalopram in HD","volume":"29","author":"Beglinger","year":"2014","journal-title":"Mov. Disord."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/cpt.147","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors","volume":"98","author":"Hicks","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/j.1552-4604.1992.tb03875.x","article-title":"Introduction of a Composite Parameter to the Pharmacokinetics of Venlafaxine and Its Active O-Desmethyl Metabolite","volume":"32","author":"Klamerus","year":"1992","journal-title":"J. Clin. Pharmacol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/FPC.0000000000000003","article-title":"PharmGKB Summary: Venlafaxine Pathway","volume":"24","author":"Sangkuhl","year":"2014","journal-title":"Pharmacogenet. Genom."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1365-2125.1996.tb00173.x","article-title":"Venlafaxine Oxidation in Vitro Is Catalysed by CYP2D6","volume":"41","author":"Otton","year":"1996","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/S0893-133X(98)00113-4","article-title":"O- and N-Demethylation of Venlafaxine in Vitro by Human Liver Microsomes and by Microsomes from CDNA-Transfected Cells: Effect of Metabolic Inhibitors and SSRI Antidepressants","volume":"20","author":"Fogelman","year":"1999","journal-title":"Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.4088\/JCP.08m04773blu","article-title":"Cytochrome P450 2D6 Phenotype Predicts Antidepressant Efficacy of Venlafaxine: A Secondary Analysis of 4 Studies in Major Depressive Disorder","volume":"71","author":"Lobello","year":"2010","journal-title":"J. Clin. Psychiatry"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2165\/11586630-000000000-00000","article-title":"Pharmacokinetics of Venlafaxine Extended Release 75 Mg and Desvenlafaxine 50 Mg in Healthy CYP2D6 Extensive and Poor Metabolizers: A Randomized, Open-Label, Two-Period, Parallel-Group, Crossover Study","volume":"31","author":"Nichols","year":"2011","journal-title":"Clin. Drug Investig."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/FTD.0b013e3181fcf94d","article-title":"Effect of Cytochrome P450 Enzyme Polymorphisms on Pharmacokinetics of Venlafaxine","volume":"33","author":"McAlpine","year":"2011","journal-title":"Ther. Drug Monit."},{"key":"ref_80","unstructured":"Dutch Pharmacogenetics Working Group (2023, January 24). Annotation of DPWG Guideline for Venlafaxine and CYP2D6. Available online: https:\/\/www.pharmgkb.org\/chemical\/pa451866\/guidelineannotation\/pa166104968."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s002280050737","article-title":"The Impact of the CYP2D6 and CYP2C19 Genotypes on Venlafaxine Pharmacokinetics in a Japanese Population","volume":"56","author":"Fukuda","year":"2000","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.neuron.2007.11.017","article-title":"Polymorphisms in the Drug Transporter Gene ABCB1 Predict Antidepressant Treatment Response in Depression","volume":"57","author":"Uhr","year":"2008","journal-title":"Neuron"},{"key":"ref_83","first-page":"21","article-title":"Serotonin Receptor 2A (HTR2A) Gene Polymorphism Predicts Treatment Response to Venlafaxine XR in Generalized Anxiety Disorder","volume":"13","author":"Lohoff","year":"2013","journal-title":"Pharm. J."},{"key":"ref_84","first-page":"48","article-title":"A 40-Basepair VNTR Polymorphism in the Dopamine Transporter (DAT1) Gene and the Rapid Response to Antidepressant Treatment","volume":"7","author":"Kirchheiner","year":"2007","journal-title":"Pharm. J."},{"key":"ref_85","unstructured":"(2023, January 16). U.S. Food and Drug Administration (FDA) Label Information for Duloxetine, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/022516lbl.pdf."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2165\/11539240-000000000-00000","article-title":"Duloxetine: Clinical Pharmacokinetics and Drug Interactions","volume":"50","author":"Knadler","year":"2011","journal-title":"Clin. Pharmacokinet."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1527-3458.2001.tb00198.x","article-title":"A Review of the Pharmacological and Clinical Profile of Mirtazapine","volume":"7","author":"Anttila","year":"2006","journal-title":"CNS Drug Rev."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2165\/0003088-200948010-00005","article-title":"Steady-State Concentrations of Mirtazapine, N-Desmethylmirtazapine, 8-Hydroxymirtazapine and Their Enantiomers in Relation to Cytochrome P450 2D6 Genotype, Age and Smoking Behaviour","volume":"48","author":"Lind","year":"2009","journal-title":"Clin. Pharmacokinet."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1097\/JCP.0b013e3182664d98","article-title":"Multicenter Study on the Clinical Effectiveness, Pharmacokinetics, and Pharmacogenetics of Mirtazapine in Depression","volume":"32","author":"Sirot","year":"2012","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"vii54","DOI":"10.1007\/s00415-006-7012-5","article-title":"Apathy and the Basal Ganglia","volume":"253","author":"Levy","year":"2006","journal-title":"J. Neurol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1176\/appi.neuropsych.14030051","article-title":"Irritability in a Prospective Cohort of Huntington\u2019s Disease Mutation Carriers","volume":"27","author":"Bouwens","year":"2015","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"ref_92","unstructured":"(2023, January 17). U.S. Food & Drug Administration (FDA) Label Information for Clozapine, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/019758s062lbl.pdf."},{"key":"ref_93","first-page":"A50","article-title":"Polymorphisms in the Oxytocin Receptor and Their Association with Apathy and Impaired Social Cognition in Huntington\u2019s Disease","volume":"93","author":"Collazo","year":"2022","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3233\/JHD-180299","article-title":"Suicidal Ideation Assessment in Individuals with Premanifest and Manifest Huntington Disease","volume":"7","author":"Wesson","year":"2018","journal-title":"J. Huntingt. Dis."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/13\/3\/385\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:39:02Z","timestamp":1760121542000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/13\/3\/385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,22]]},"references-count":94,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["jpm13030385"],"URL":"https:\/\/doi.org\/10.3390\/jpm13030385","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,22]]}}}